Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Feb;128(3):485-493.
doi: 10.1111/1471-0528.16411. Epub 2020 Aug 2.

PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis

Q Lin  1 , W Liu  2 , S Xu  1 , H Shang  1 , J Li  1 , Y Guo  3 , J Tong  1
Affiliations
Meta-Analysis

PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis

Q Lin et al. BJOG. 2021 Feb.

Abstract

Background: Up to 70% of patients with advanced ovarian cancer have a relapse after primary therapy. New agents and approaches are urgently needed to avoid or slow down this recurrence.

Objectives: To investigate the efficacy of PARP inhibitors (PARPis) as maintenance treatment in patients with newly diagnosed advanced ovarian cancer.

Search strategy: PubMed, MEDLINE, EMBASE, Cochrane Library and Web of Science databases.

Selection criteria: All randomised clinical trials (RCTs) that compared PARPis with placebo as first-line maintenance therapy in ovarian cancer.

Data collection and analysis: Two reviewers extracted data. Pooled hazard ratio (HR) and risk ratio (RR) with 95% confidence interval (CI) were calculated.

Main results: PARPis were associated with significant improvement of progression-free survival (PFS) in advanced epithelial ovarian cancer (AeOC) (HR = 0.53, 95% CI 0.40-0.71; P < 0.0001). The benefit was not only in women with BRCA mutations (HR = 0.35, 95% CI 0.29-0.42; P < 0.00001) and homologous recombination deficiency (HRD) (HR = 0.43, 95% CI 0.32-0.60; P < 0.00001), but also in those with nonmutated BRCA (HR = 0.72, 95% CI 0.63-0.82; P < 0.00001) and even non-HRD (HR = 0.83, 95% CI 0.70-0.99; P = 0.04).

Conclusions: PARP inhibitors are effective as maintenance therapy among patients with newly diagnosed advanced ovarian cancer after platinum-based chemotherapy, regardless of BRCA mutation or HRD status.

Tweetable abstract: PARPis provide a significant PFS benefit as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Keywords: Maintenance therapy; PARP inhibitors; ovarian cancer.

PubMed Disclaimer

Comment in

References

    1. HendersonJT, WebberEM, SawayaGF. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA2018;319:595-606.
    1. BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin2018;68:394-424.
    1. ArmstrongDK, BundyB, WenzelL, HuangHQ, BaergenR, LeleS, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med2006;354:34-43.
    1. BurgerRA, BradyMF, BookmanMA, FlemingGF, MonkBJ, HuangH, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med2011;365:2473-83.
    1. PerrenTJ, SwartAM, PfistererJ, LedermannJA, Pujade-LauraineE, KristensenG, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med2011;365:2484-96.

Publication types

MeSH terms

Substances

LinkOut - more resources